Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, a clinical professor in Medical Oncology at the University College Dublin, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.
The ongoing DASL-HiCAP trial is testing the addition of darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and definitive or salvage radiation in men with high-risk prostate cancer.
Although the trial is currently recruiting patients, the coronavirus disease 2019 pandemic will likely delay the full accrual process, McDermott says.
Additionally, accrual needs to commence in multiple different centers worldwide, explains McDermott. Should these sites open within 2020, the accrual process will commence for a period of about 2 years.
As men with prostate cancer can recur years into remission, follow-up will likely take several years to determine whether the primary end point of the trial was met, McDermott concludes.